Lataa...
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab (Cosentyx(®)), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and sympt...
Tallennettuna:
| Julkaisussa: | Drugs |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer International Publishing
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6422944/ https://ncbi.nlm.nih.gov/pubmed/30793255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01075-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|